Ravi Vij

Active 1999–2026

147
Papers
21,104
Citations
75
h-index
143
i10-index

Citations

Citations per year for Ravi Vij1999: 1 citations2000: 4 citations2001: 3 citations2002: 7 citations2003: 5 citations2004: 5 citations2005: 4 citations2006: 2 citations2007: 6 citations2008: 6 citations2009: 25 citations2010: 41 citations2011: 87 citations2012: 128 citations2013: 206 citations2014: 242 citations2015: 219 citations2016: 223 citations2017: 249 citations2018: 233 citations2019: 781 citations2020: 899 citations2021: 964 citations2022: 761 citations2023: 599 citations2024: 1,038 citations2025: 441 citations2026: 19 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,003 citing papers, 28.6% of this breakdownChina: 764 citing papers, 7.3% of this breakdownGermany: 669 citing papers, 6.4% of this breakdownItaly: 645 citing papers, 6.1% of this breakdownUnited Kingdom: 549 citing papers, 5.2% of this breakdownFrance: 521 citing papers, 4.9% of this breakdownSpain: 474 citing papers, 4.5% of this breakdownCanada: 384 citing papers, 3.6% of this breakdownNetherlands: 335 citing papers, 3.2% of this breakdownAustralia: 230 citing papers, 2.2% of this breakdownJapan: 219 citing papers, 2.1% of this breakdownBelgium: 189 citing papers, 1.8% of this breakdown
0%28.6%Other 24.1%

Fields

  • Medicine73.2%
  • Biochemistry, Genetics and Molecular Biology19.3%
  • Immunology and Microbiology5.4%
  • Engineering0.6%
  • Computer Science0.3%
  • Mathematics0.3%
  • Other0.9%

Topics

  • Multiple Myeloma Research and Treatments12.6%
  • Protein Degradation and Inhibitors6.5%
  • Acute Myeloid Leukemia Research5.3%
  • Hematopoietic Stem Cell Transplantation4.7%
  • CAR-T cell therapy research4.5%
  • Cancer Genomics and Diagnostics3.1%
  • Other63.3%

Coauthors

All papers

Open in search
  1. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 705

  2. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2019 cited by 616

  3. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Hermann Einsele, Philippe Moreau - Leukemia 2022 cited by 240

  4. Epigenetic regulation during cancer transitions across 11 tumour types

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Russell K. Pachynski, Julie K. Schwarz, William E. Gillanders, Albert H. Kim, Ravi Vij, John F. DiPersio, Sidharth V. Puram, Milan G. Chheda, Katherine C. Fuh, David G. DeNardo, Ryan C. Fields, Feng Chen, Benjamin J. Raphael, Li Ding - Nature 2023 cited by 200

  5. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Raymond L. Comenzo, Monika Engelhardt, Thomas Illmer, Philip Vlummens, Chantal Doyen, Thierry Façon, Lionel Karlin, Aurore Perrot, Klaus Podar, Michael Kauffman, Sharon Shacham, Lingling Li, Shijie Tang, Carla Picklesimer, Jean‐Richard Saint‐Martin, Marsha Crochiere, Hua Chang, Samir Parekh, Yosef Landesman, Jatin J. Shah, Paul G. Richardson, Sundar Jagannath - New England Journal of Medicine 2019 cited by 673

  6. Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , S. Vincent Rajkumar, Shaji Kumar, Rafaël Fonseca, Greg Ahmann, P. Leif Bergsagel, A. Keith Stewart, Craig C. Hofmeister, Yvonne A. Efebera, Sundar Jagannath, Ajai Chari, Suzanne Trudel, Donna Reece, Jeffrey Wolf, Thomas Martin, Todd M. Zimmerman, Cara A. Rosenbaum, Andrzej Jakubowiak, Daniel Lebovic, Ravi Vij, Keith Stockerl-Goldstein - Cancer Cell 2014 cited by 1,004

  7. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 123

  8. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Madina Sukhanova, Randall W. Knoebel, Wendy Stock, Timothy A. Graubert, Matthew J. Walter, Peter Westervelt, Daniel C. Link, John F. DiPersio, Timothy J. Ley - New England Journal of Medicine 2016 cited by 784

  9. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2017 cited by 311

  10. Initial genome sequencing and analysis of multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robb Onofrio, Trevor J. Pugh, S. Vincent Rajkumar, Alex H. Ramos, David S. Siegel, Andrey Sivachenko, A. Keith Stewart, Suzanne Trudel, Ravi Vij, Douglas Voet, Wendy Winckler, Todd M. Zimmerman, John D. Carpten, J.M. Trent, William C. Hahn, Levi A. Garraway, Matthew Meyerson, Eric S. Lander, Gad Getz, Todd R. Golub - Nature 2011 cited by 1,455

  11. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood 2017 cited by 527

  12. SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution

    Authors: , , , , , , , , , , , , , , , , - PLoS Computational Biology, PLoS Comput. Biol. 2014 cited by 495

  13. Co-evolution of tumor and immune cells during progression of multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 cited by 136

  14. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2015 cited by 654

  15. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sunita Nathan, Aziz Nazha, Taiga Nishihori, Sagar S. Patel, Attaphol Pawarode, David A. Rizzieri, Bipin N. Savani, Sachiko Seo, Melhem Solh, Celalettin Üstün, Marjolein van der Poel, Leo F. Verdonck, Ravi Vij, Baldeep Wirk, Betül Oran, Ryotaro Nakamura, Bart L. Scott, Wael Saber - JAMA Oncology 2022 cited by 78

  16. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael E. Kelly, Michele Seiler, Cara A. Rosenbaum, Parameswaran Hari, Marcelo C. Pasquini, Mary M. Horowitz, Thomas C. Shea, Steven M. Devine, Kenneth C. Anderson, Charles Linker - New England Journal of Medicine 2012 cited by 1,143

  17. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ashraf Badros, Philippe Moreau, K Kim, P R Otero, J H Lee, Chaim Shustik, Daniel D. Waller, Wee Joo Chng, Shuji Ozaki, J-J Lee, Javier de la Rubia, Hyeon‐Seok Eom, Laura Rosiñol, Juan José Lahuerta, Anna Sureda, Jin Seok Kim, B G M Durie - Leukemia 2017 cited by 354

  18. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2018 cited by 198

  19. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew A. Lunning, Michael P. Chu, Carter Milner, Allyson Harroff, Mark E. Graham, Spencer H. Shao, Jyothi Dodlapati, Carlos Fernández de Larrea, Leonard Klein, Charles Kuzma, Rafaël Fonseca, Gemma Azaceta, Miquel Granell, Carmen Martínez‐Chamorro, Rama Balaraman, Carlos Fernandes da Silva, Anabelle Chinea, Caitlin Costello, Suman Kambhampati, DeQuincy Andrew Lewis, Michael L. Grossbard, Kathleen J. Yost, Robert Robles, Michaël Sébag, Wayne Harris, Justinian R. Ngaiza, Michael Bär, Marie Shieh, Fredrick Min, Adedayo A. Onitilo, Fabio Volterra, William Wachsman, Madhuri Yalamachili, Eugènia Abella, Larry J. Anderson, Joan Bargay, Hani Hassoun, Gerald C Hsu, Hakan Kaya, Alex R. Menter, Dilip Patel, Donald Richards, William B. Solomon, Robert F. Anderson, Sumeet Chandra, Miguel Á. Conde, Saulias Girnius, May Matkiwsky, Isabel Krsnik, Shaji Kumar, Albert Oriol, Paula Rodríguez, Vivek Roy, Shanti Srinivas, Ronald G. Steis, Austin Christofferson, Sara Nasser, Jessica L. Aldrich, Christophe Legendre, Brooks A. Benard, C. S. Miller, Bryce Turner, Ahmet Kurdoglu, Megan Washington, Venkata D. Yellapantula, Jonathan Adkins, Lori Cuyugan, Martin Boateng, Adrienne Helland, Shari Kyman and 29 more - Nature Genetics 2024 cited by 75

  20. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy

    Authors: , , , , , , , , , , , - Leukemia 2021 cited by 63

  21. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ravi Vij, John F. DiPersio - Nature Medicine 2023 cited by 73

  22. Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood 2023 cited by 26

  23. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Saad Z. Usmani, Ravi Vij, Jeffrey L. Wolf, Jeffrey A. Zonder, P. Leif Bergsagel, Daniel Auclair, Hearn Jay Cho, Dan R. Robinson, Arul M. Chinnaiyan - Nature Communications 2022 cited by 91

  24. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2020 cited by 75